Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

41. Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores

Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores Article

Evidence-Based Medicine (Requires free registration)2014

42. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children

MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page

NIHR HTA programme2013

43. Magnesium for alcohol withdrawal.

Magnesium for alcohol withdrawal. BACKGROUND: Patients have been given magnesium to treat or prevent alcohol withdrawal syndrome (AWS). Evidence to support this practice is limited, and is often based on the controversial link between hypomagnesaemia and AWS. OBJECTIVES: To assess the effects of magnesium for the prevention or treatment of AWS in hospitalised adults. SEARCH METHODS: We searched the Cochrane Drugs and Alcohol Group Register of Controlled Trials (August 2012), PubMed (from 1966 (...) to August 2012 ), EMBASE (from 1988 to August 2012), CINAHL (from 1982 to March 2010), Web of Science (1965 to August 2012). We also carried out Internet searches. SELECTION CRITERIA: Randomised or quasi-randomised trials of magnesium for hospitalised adults with, or at risk for, acute alcohol withdrawal. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data with a standardised data extraction form, contacting the correspondence investigator if the necessary information

Cochrane2013

44. Magnesium sulphate for women at term for neuroprotection of the fetus.

Magnesium sulphate for women at term for neuroprotection of the fetus. BACKGROUND: Magnesium sulphate is extensively used in obstetrics for the treatment and prevention of eclampsia. A recent meta-analysis has shown that magnesium sulphate is an effective fetal neuroprotective agent when given antenatally to women at risk of very preterm birth. Term infants account for more than half of all cases of cerebral palsy, and the incidence has remained fairly constant. It is important to assess (...) if antenatal administration of magnesium sulphate to women at term protects the fetus from brain injury, and associated neurosensory disabilities including cerebral palsy. OBJECTIVES: To assess the effectiveness of magnesium sulphate given to women at term as a neuroprotective agent for the fetus. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trial Register (31 July 2012) and the reference lists of other Cochrane reviews assessing magnesium sulphate in pregnancy. SELECTION

Cochrane2013

45. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials

Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled (...) , randomized clinical trials Gu WJ, Wu ZJ, Wang PF, Aung LHH, Yin RX CRD summary The authors concluded that intravenous magnesium significantly reduced the incidence of postoperative atrial fibrillation after coronary artery bypass grafting. The conclusions reflect the results but limitations in the review's search and quality assessment methods coupled with an indication that the pooled results may have been affected by publication bias make the reliability of the conclusions uncertain. Authors' objectives To assess

DARE.2013

46. Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia

Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia Article Text Aetiology Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk

Evidence-Based Mental Health2013

47. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Pre Prev venting recurrent h enting recurrent hypomagnesaemia: or ypomagnesaemia: oral al magnesium gly magnesium glycerophosphate cerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate

National Institute for Health and Clinical Excellence - Advice2013

48. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies

Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies Wolf HT, Hegaard HK, Greisen G, Huusom L, Hedegaard M CRD summary The review of observational studies concluded that antenatal treatment with magnesium (...) sulphate during premature delivery seemed to be associated with a reduced incidence of infant cerebral palsy and a decrease in the risk of infant mortality. Limitations of the included studies and in the review process mean that the reliability of these conclusions is uncertain. Authors' objectives To review the effect of magnesium sulphate on the risk of infant cerebral palsy and mortality in premature deliveries in observational studies. Searching PubMed, EMBASE and The Cochrane Library were searched

DARE.2012

50. Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block

Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block 22012543 2011 12 28 2012 04 25 2013 11 21 1496-8975 59 1 2012 Jan Canadian journal of anaesthesia = Journal canadien d'anesthesie Can J Anaesth Magnesium added to bupivacaine prolongs the duration of analgesia after interscalene nerve block. 21-7 10.1007/s12630-011-9604-5 Local anesthetic adjuvants have been studied previously in an attempt to prolong the duration of analgesia after peripheral nerve (...) blockade. Magnesium has been shown to have an antinociceptive effect in animal and human pain models. We evaluated the effects of adding magnesium sulphate to long-acting local anesthetics for interscalene nerve block to prolong the duration of analgesia and improve the analgesic quality. We enrolled 66 patients undergoing arthroscopic rotator cuff repair. The interscalene nerve block was performed with 0.5% bupivacaine 20 mL with epinephrine (1:200,000) plus either 10% magnesium sulphate 2 mL

EvidenceUpdates2012

51. Magnesium for Pre-Eclampia

Magnesium for Pre-Eclampia Magnesium for Pre-Eclampia – TheNNTTheNNT Magnesium Sulfate for Women with Preeclampsia 90 for seizure In Summary, for those who received the magneisum: Benefits in NNT For the mother: 98.8% saw no benefit 1.2% were helped by preventing a seizure For the child: 100% saw no benefit 0% were helped by avoiding mortality, NICU stay, preterm delivery For the mother: 1 in 90 were helped (seizure prevented) For the child: None were helped (death, NICU stay, avoiding preterm (...) maternal death). Although the mechanism is unclear magneisum sulfate has been used to prevent eclampsia since the 1950s. In this cochrane review, 11,444 women in 15 randomized trials were recruited from a mix of high, middle, and low income countries. The largest is the 33-country MagPie Trial comparing intravenous magnesium to placebo. The study was published in 2002 and at >10,000 subjects accounts for more than 87% of those in the review. The use of magnesium sulfate was associated with a greater

theNNT2012

52. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth.

Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. BACKGROUND: The effectiveness of antenatal magnesium sulphate for neuroprotection of the fetus, infant, and child prior to very preterm birth, when given to women considered at risk of preterm birth, has been established. There is currently no consensus as to the regimen to use in terms of the dose, duration, the use of repeat dosing and timing. OBJECTIVES: To assess the comparative (...) effectiveness and adverse effects of different magnesium sulphate regimens for neuroprotection of the fetus in women considered at risk of preterm birth. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2011). SELECTION CRITERIA: Randomised trials comparing different magnesium sulphate regimens when used for neuroprotection of the fetus in women considered at risk of preterm birth. We planned to include cluster trials. We planned to exclude quasi

Cochrane2012

53. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial.

Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. 22633825 2012 07 09 2012 07 23 2016 11 22 1474-547X 380 9836 2012 Jul 07 Lancet (London, England) Lancet Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. 44-9 10.1016/S0140-6736(12)60724-7 Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving (...) the outcome of delayed cerebral ischaemia. We did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage. We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South America. We randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratified by centre) patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were admitted to hospital within

Lancet2012 Full Text: Link to full Text with Trip Pro

54. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy

Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy 21596876 2011 07 26 2011 09 28 2012 11 15 1526-7598 113 2 2011 Aug Anesthesia and analgesia Anesth. Analg. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. 390-7 10.1213/ANE.0b013e31821d72bc In a randomized, double-blind, prospective study, we investigated whether an intraoperative high versus low dose of remifentanil (...) increased postoperative hyperalgesia and whether magnesium can prevent remifentanil-induced hyperalgesia. Ninety patients undergoing thyroidectomy were randomly assigned to 1 of 3 groups. Remifentanil was intraoperatively infused at 0.05 μg/kg/min (group LO) or 0.2 μg/kg/min (groups HI and HM). Patients in group HM received MgSO(4) 30 mg/kg at induction followed by an intraoperative infusion of 10 mg/kg/h. Mechanical pain thresholds on the forearm and periincisional area were assessed by von Frey

EvidenceUpdates2011

56. Magnesium-Essentials for Anesthesiologists

Magnesium-Essentials for Anesthesiologists 21364460 2011 03 23 2011 05 20 2013 11 21 1528-1175 114 4 2011 Apr Anesthesiology Anesthesiology Magnesium--essentials for anesthesiologists. 971-93 10.1097/ALN.0b013e318210483d Magnesium plays a fundamental role in many cellular functions, and thus there is increasing interest in its role in clinical medicine. Although numerous experimental studies indicate positive effects of magnesium in a variety of disease states, large clinical trials often give (...) conflicting results. However, there is clear evidence for magnesium to benefit patients with eclampsia or torsades de pointes arrhythmias. In addition, magnesium seems to have antinociceptive and anesthetic as well as neuroprotective effects, yet well-designed large clinical trials are required to determine its actual efficacy in pain management or in the state of stroke or subarachnoid hemorrhage. The current review aims to provide an overview of current knowledge and available evidence with respect

EvidenceUpdates2011

57. Calcium acetate and magnesium carbonate (Osvaren) - treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis

Calcium acetate and magnesium carbonate (Osvaren) - treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis

Scottish Medicines Consortium2011

58. Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage

Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage BestBets: Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Report By: Daniel Horner - ST4 Emergency Medicine / Critical Care Search checked by Craig Ferguson - SpR Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 1st May (...) 2010 Date Completed: 27th January 2011 Last Modified: 27th January 2011 Status: Green (complete) Three Part Question In a patient presenting with [aneurysmal subarachnoid haemorrhage] does [early elevation of serum magnesium by administration of intravenous magnesium sulphate] lead to a reduction in [subsequent vasospasm incidence, morbidity or mortality rates] Clinical Scenario A 40 year old female attends the emergency department as a standby call. Her partner gives you a history of acute

BestBETS2011

59. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 21189381 2011 01 31 2011 03 10 2016 12 15 1527-7755 29 4 2011 Feb 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. 421-7 10.1200/JCO.2010.31.5911 Cumulative sensory neurotoxicity (sNT) is the dose (...) -limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT. Patients with colon cancer undergoing adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

60. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial

The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial 21226679 2011 01 13 2011 02 18 2013 11 21 1532-5415 59 1 2011 Jan Journal of the American Geriatrics Society J Am Geriatr Soc The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. 82-90 10.1111/j.1532-5415.2010.03232.x (...) To determine whether nightly administration of melatonin, magnesium, and zinc improves primary insomnia in long-term care facility residents. Double-blind, placebo-controlled clinical trial. One long-term care facility in Pavia, Italy. Forty-three participants with primary insomnia (22 in the supplemented group, 21 in the placebo group) aged 78.3 ± 3.9. Participants took a food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp) or placebo (100 g pear pulp) every

EvidenceUpdates2011